NCT06586216View on ClinicalTrials.gov

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

February 13, 2025

Study Completion Date

February 13, 2025

Conditions

COVID-19

Interventions

DRUG

PF-07817883

Experimental

Trial Locations (3)

33014

Clinical Pharmacology of Miami, Miami

33603

Genesis Clinical Research, LLC, Tampa

55114

Prism Research LLC dba Nucleus Network, Saint Paul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT06586216 - A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883. | Biotech Hunter | Biotech Hunter